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Abstract
Testicular germ cell tumor (TGCT) is the most
common tumor type among adolescent and young
adult males. Familial clustering and bilateral disease
are suggestive of a genetic predisposition among a
subgroup of these patients, but susceptibility genes
for testicular cancer have not yet been identified.
However, suggestive linkage between disease and
genetic markers has been reported at loci on
chromosome arms 3q, 5q, 12q, 18q, and Xq. We
have analyzed primary familial /bilateral (n=20) and
sporadic (n=27) TGCTs, including 28 seminomas
and 19 nonseminomas, for allelic imbalance (AI)
within the autosomal regions. DNA from all tumors
were analyzed by fluorescent polymerase chain
reaction of 22 polymorphic loci at 3q27 - ter,
5q13–35.1, 12q21-ter, and 18q12–ter. All tumor
genotypes were evaluated against their correspond-
ing constitutional genotypes. The percentages of
TGCTs with genetic changes at 3q, 5q, 12q, and
18q, were 79%, 36%, 53% and 43%, respectively.
The frequencies at 3q and 12q in nonseminomas
were significantly higher than in seminomas
(P=.003 and P=.004). In order to evaluate changes
at hemizygous Xq loci, five loci were analyzed by
co - amplification with an autosomal reference
marker known to reveal retained heterozygosity in
the tumor DNA. Gain of Xq sequences was seen
in more than 50% of the tumors. The degree of
amplification varied among the loci in each of five
tumors, and based on these breakpoints, a com-
mon region of overlapping gains was found at
Xq28. No significant differences were found be-
tween the frequencies of genetic changes in
familial /bilateral versus sporadic tumors, an obser-
vation speaking in disfavor of the existence of a
single susceptibility gene for TGCT in any of the
analyzed regions. Our data suggest that gain of
genetic material at distal Xq and losses at 5q and
18q contribute to establishment of seminomas,
whereas imbalances at 3q as well as gain at distal
part of 12q are associated with further progression
into nonseminomas. Neoplasia (2001) 3, 196–203.
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Introduction
Testicular germ cell tumor (TGCT) is the most common
malignancy among young white males, and the incidence is
increasing rapidly [1–3] . TGCTs are subdivided into two
main histological entities: the undifferentiated seminomas,
and the nonseminomas, composed of embryonic neoplastic
germ cells, which mimic the histogenesis of an early embryo.
Seminomas are believed to arise from a carcinoma in situ
stage, and may develop into nonseminomas [4,5 ] . TGCTs
are characterized by overrepresentation of chromosome arm
12p, often through the presence of isochromosome 12p
[6,7] , and nonrandom losses and gains of certain chromo-
somes [5,8–11] . TGCTs are nearly always hyperdiploid,
and are frequently in the triploid range [5,12] .
The cause of TGCT remains unknown. Increased
incidence over time and correlation with socioeconomic
class point toward influence of environmental factors. The
observed familial clustering of TGCT, particularly among
brothers, may be due to their exposure to similar environ-
ments, in utero, or as children [13–16] . However, the
four- fold increased risk for father–son transmission
indicates a genetic predisposition [14] . Men with GCT in
one testis are at increased risk of developing a contrala-
teral malignancy [17] . The presence of bilateral neoplastic
changes supports a genetic susceptibility for TGCT, but is
Neoplasia . Vol. 3, No. 3, 2001, pp. 196 –203
www.nature.com/neo
196
Abbreviations: AI, allelic imbalance; CGH, comparative genomic hybridization; GCT, germ
cell tumor; ITCLC, international testicular cancer linkage consortium; LOH, loss of
heterozygosity; TGCT, testicular germ cell tumor
Address all correspondence to: Ragnhild A. Lothe, Department of Genetics, Institute for
Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo N - 0310, Norway.
E-mail: rlothe@radium.uio.no
1This study was supported by grants from the NCS (R. A. L. ).
Received 28 December 2000; Accepted 24 February 2001.
Copyright# 2001 Nature Publishing Group All rights reserved 1522-8002/01/$17.00
RESEARCH ARTICLE
also consistent with exposure to environmental carcino-
gens. Statistical analyses by Nicholson and Harland [18]
suggest that patients with bilateral disease carry the same
genetic predisposition as familial cases, and that approx-
imately one third of all men with TGCT is genetically
predisposed to the disease.
The International Testicular Cancer Linkage Consortium
(ITCLC) analyzed 220 polymorphic microsatellite loci
throughout the autosomal genome in selected families with
two or more cases of testicular cancer. None of the markers
showed conclusive evidence of a close map position to a
TGCT predisposing gene, but loci on chromosome arms 3q,
5q, 12q, and 18q showed suggestive linkage to the disease
[19] . Recently, Rapley et al. [20] found significant linkage
between markers at Xq27 and TGCT within a subset of
TGCT families (hLOD=4.7).
In the present study, series of familial /bilateral and
sporadic TGCTs, comparable according to histology and
percentage of tumor cells, were analyzed for somatic
alterations at polymorphic microsatellite loci, within and near
the five candidate regions.
Materials and Methods
Samples from the TGCT Patients
Primary tumor biopsies and corresponding peripheral
blood samples were obtained from 47 Norwegian TGCT
patients. The patients were grouped into cases of familial
and/or bilateral TGCT (n=20) and cases of sporadic
cancer (n=27). Among the 20 familial /bilateral TGCTs,
13 were bilateral, 11 had affected family members, and
thus, 4 had both bilateral tumors and familial occurrence of
the disease. Four of the familial /bilateral TGCTs were from
patients with history of cryptorchidism. Median age at
diagnosis was 29 years for the familial /bilateral group and
30 for the sporadic.
Three 5 m sections were taken from different parts of
each frozen tumor sample prior to DNA isolation. The
sections were stained with hematoxylin and eosin and
visually evaluated by light microscopy. The various tumor
components were described according to the WHO’s
recommendations [21] , and percentage of intact neoplastic
cells was estimated for each section. An average of the three
sections per tumor sample was calculated. Among all
tumors, an average of 75% tumor cells was found (range
30–100%). The familial /bilateral and sporadic tumor groups
were comparable according to histology and estimated
percentage of tumor cells. A total of 28 seminomas included
13 familial /bilateral and 15 sporadic tumors, and among the
19 nonseminomas, 7 were familial /bilateral and 12 sporadic
TGCTs.
DNA was isolated from blood and tumor tissues by
applying the phenol /chloroform extraction principle [22] .
Microsatellite Analyses
Throughout the five candidate regions suspected to carry
a TGCT susceptibility gene [19,20,23] , we investigated
markers at 27 microsatellite loci (Figure 1 ). Primer sequen-
ces and allele diversities were obtained from the Human
Genome Database [24] and the Ge´ne´thon human linkage
map [25] .
3q27- ter Five members of a cancer-prone Canadian
kindred who all developed TGCT [26] shared a common
haplotype for three markers in the 3q telomeric region. We
analyzed the same three markers, D3S1601, D3S2748, and
D3S1265, which are all located in the 3q27- ter candidate
region [19] .
5q13–35.1 The candidate region at 5q suggested by
ITCLC lies between the markers D5S428 (maps together
with the more informative marker D5S617) and D5S421.
Leahy et al. [23] suggested a target region between
D5S428 and D5S409. The marker D5S346 is closely
located to adenomatous polyposis coli (APC) [27] , a
candidate tumor-suppressor gene on 5q21 [28,29] . Addi-
tional three markers were included to flank and refine this
candidate region.
12q21- ter The ITCLC results showed increasing linkage
evidence along the long arm of chromosome 12, as the
Figure 1. Map positions of the analyzed microsatellite markers. All markers have (CA )n dinucleotide repeats, except D5S1456 that has a (GATA )n tetranucleotide
repeat. Numbers to the left of each ideogram indicate the chromosome bands. Numbers to the right of each autosomal genetic map indicate the sex - averaged map
distance between the markers in centi Morgan ( cM). For the X chromosome, this value represents the female recombination ( fcM) value, based on the Ge´ne´thon
human linkage map [ 25 ] .
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markers became more distal [19] . We therefore analyzed
three markers in the q telomeric region (12q24.3) as well as
one more proximal marker.
18q12–ter The suggestive linkage evidence at 18q spanned
several chromosome bands. D18S554 at 18q23 was found
to be the marker with the overall highest linkage score
(nonparametric linkage=1.6) in the ITCLC study [19] . This
and two flanking markers, D18S58 and D18S461, were
included in the present study. Five additional markers
mapping to 18q12–21 were also analyzed due to the
clustering of putative tumor-suppressor genes (e.g. DCC,
SMAD2, and DPC4 ) in this region.
Xq27- ter Five markers were chosen to cover and flank the
Xq27 region defined by Rapley et al. [20] .
Polymerase chain reaction (PCR) conditions The 10 l
reaction volume consisted of 1 GeneAmp PCR buffer with
1.5 mM MgCl2 (Applied Biosystems, Foster City, CA, USA),
2 to 5 pmol of each primer (DNA Technology, Aarhus,
Denmark), 200 M each of the four dNTPs (Amersham
Pharmacia Biotech., London, UK), 0.4 units AmpliTaq DNA
Polymerase (Applied Biosystems, Foster City, CA, USA),
and 50 ng DNA template. The forward primers were 50 -
labeled with HEX, TET, or 6-FAM fluorochromes. Three
primer pairs were multiplexed in each PCR.
The PCR was carried out in a 96-well format using an MJ
PTC-200 thermocycler (MJ Research, Watertown, MA,
USA). Two minutes of denaturation at 948C was followed
by 27 cycles of 30 seconds denaturation at 948C, 75 seconds
annealing at 558C, and 15 seconds elongation at 728C,
before 6 minutes final extension at 728C.
Detection of PCR products PCR products from two
multiplex reactions (20.8 l ) were pooled to allow
capillary electrophoresis of six loci simultaneously. This
was further mixed with 0.5 l GeneScan-350 [TAMRA]
Size Standard (Applied Biosystems, Foster City, CA,
USA) in 12 l deionized formamide, CH3NO (Kodak
Eastman Chemical, New Haven, CT, USA), followed by
capillary electrophoresis on an ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
The samples were electrokinetically injected for 1 to 20
seconds into a 4750 m capillary, and electrophoresed
at 15 kV for 23 minutes. The resulting electropherograms
represented relative intensities of four different fluorescent
dyes with respect to electrophoresis time ( i.e., sizes of
DNA fragments). The softwares GeneScan 3.1 and
GenoTyper 2.1 (Applied Biosystems, Foster City, CA,
USA) were used to analyze the electropherograms, before
the allele peak heights were further exported to Microsoft
Excel.
Determination of allelic imbalance (AI) and loss of hetero-
zygosity (LOH) A semiquantitative expression of AI, QLOH,
was calculated as the ratio of the allele intensity ratios in
tumor and blood (constitutional ) DNA, as in [ tumor allele 1/
tumor allele 2] / [blood allele 1/blood allele 2] . When this
value was greater than one, QLOH was set to be the inverse.
For designation of AI at a locus, we required two independent
amplifications of the specific marker where both showed
QLOH values less than or equal to 0.84 [30] . The mean
QLOH value was used further. The 0.84 cut-off value was
determined due to the standard deviation of QLOH among
samples with retained heterozygosity (SD=0.083). This
gives a probability of 99.75% that a scored AI is real, and not
due to technical error, given independence between the
errors of repeated PCRs [30] .
The TGCTs comprise a heterogeneous group of
neoplasms, both with respect to different tumor compo-
nents, and the varying presence of normal cells in the
tumor biopsies. These factors must be considered when
scoring LOH. In the present study, LOH was scored when
QLOH was less than or equal to the estimated fraction of
normal cells in the tumor biopsy. The latter is of course
somewhat subjective, but still, this way of LOH scoring is
safer than the usual practice, designating all tumors as
LOH if their QLOH values are below a certain fixed
threshold value. However, no matter how low the QLOH
value is, it is still possible that it reflects gain of one allele,
and not loss of the other. Therefore, we obtained
additional information on the nature of our AIs by
comparing our results to those of a separate study,
analyzing 33 of the same tumors by comparative genomic
hybridization (CGH) [31] .
Determination of the results for the X chromosome markers
An AI approach is not possible for investigation of X
chromosome markers in male tumors because of their
constitutional hemizygosity. Together with the X markers,
we therefore co-amplified an autosomal reference marker
with QLOH value known to be close to 1.00. We then
compared the peak heights of the X markers with the peak
heights of the reference, in both blood and tumor DNA, to
see whether the X markers were over- or underrepre-
sented in tumor DNA, compared to the reference. The
results were always confirmed by a second independent
PCR.
Results
Analysis of AI and LOH at Autosomal Loci
Forty-seven TGCTs were analyzed for AI and LOH at 22
autosomal polymorphic loci covering four autosomal candi-
date regions for TGCT susceptibility. The distributions of the
tumors’ average QLOH values are shown in Figure 2. The
frequencies of tumors showing alterations ( i.e., confirmed
QLOH0.84) at one or more loci at 3q, 5q, 12q, or 18q were
79%, 36%, 53%, and 43%, respectively (Table 1). The
frequency of changes in the 3q region was significantly
higher than for each of the 5q, 12q, and 18q regions
(P<.001, P=.009, and P<.001, respectively).
LOH was found in 32%, 21%, 9%, and 28% of the tumors
at the 3q, 5q, 12q, and 18q loci, respectively (Table 1). The
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LOH frequency at the 12q loci was significantly lower than for
each of the 3q, 5q, and 18q regions (P=.005, .05, and .02,
respectively).
Breakpoints in the AI /LOH pattern within the investigated
regions were seen in six tumors. At the 5q region, two tumors
showed retained heterozygosity at D5S644, but AI at the
more distal markers. At 12q, one tumor revealed retained
heterozygosity at D12S81, but increasingly stronger AI
toward the telomere (Figure 3A ). Another tumor showed AI
at D12S324, but retained heterozygosity for the flanking
markers. At 18q, two tumors showed either AI or retained
heterozygosity at D18S57, and LOH or AI at the more distal
markers, respectively.
Familial /Bilateral versus Sporadic
The overall frequencies of tumors showing AI or LOH in all
investigated regions were 51% among the familial /bilateral
and 55% among the sporadic tumors. No significant differ-
ences were seen comparing the familial /bilateral and the
sporadic tumors for genetic changes within the individual
regions (Table 1). For 3q and 12q, AI /LOH was found in
85% and 59% of the sporadic tumors, whereas 70% and
45%, respectively, among the familial /bilateral (P=.21 and
P=.33).
Seminomas versus Nonseminomas
The overall number of changes was significantly higher
among the nonseminomas than for the seminomas
(P<.001). The frequencies of genetic changes at 3q and
12q in nonseminomas (100% and 79%, respectively) were
significantly higher than in seminomas (64% and 36%;
P=.003 and P=.004, respectively).
Analysis of X Chromosome Loci
Thirty -eight of the 47 pairs of blood/ tumor DNA were
analyzed at five loci on the X chromosome. In general, the
peak heights showed increased values from blood to tumor,
relative to their co-amplified autosomal reference markers.
Though heterozygous (QLOH>0.84), the reference markers
may still have altered copy numbers in tumor, and thus, the X
markers’ status as gained or lost is not definite by this
approach. More interesting are the observed breakpoints
between the peak heights of neighboring X chromosome
markers, relative to their common reference marker. Five
tumors with such breakpoints were seen, and altogether,
Table 1. Frequencies of Tumors Showing AI, LOH, and the Total Frequency of Change (AI+LOH).
All tumors
(n=47 ) (% )
Familial / bilateral
(n=20 ) (%)
Sporadic
(n=27 ) (% )
Seminomas
(n=28 ) (%)
Nonseminomas
(n=19 ) (% )
3q AI 47 30 60 36 63
LOH 32 40 26 29 37
Total 79 70 85 64 100
5q AI 15 20 11 18 11
LOH 21 25 19 18 26
Total 36 45 30 36 37
12q AI 45 40 48 29 68
LOH 9 5 11 7 11
Total 53 45 59 36 79
18q AI 15 15 15 14 16
LOH 28 25 30 21 37
Total 43 40 44 36 53
Figure 2. The distribution of QLOH ( x -axis ) for each of the analyzed autosomal regions. For all tumors, an average QLOH value was found along each of the four
investigated autosomal regions, and the distributions are shown in the histograms above, e.g., if a tumor showed 0.39, 0.43, and 0.41 for the three loci at
chromosome arm 3q, the average value of 0.41 contributed to the bar representing QLOH values from 0.4 to 0.5 in the 3q histogram. The y -axis shows the number of
tumors in each histogram group. The figure illustrates the infrequent LOH at chromosome arm 12q, where only one average QLOH value is less than 0.5. For the
chromosome arms 3q, 5q, and 18q, there were 10, 9, and 11 tumors with average QLOH values less than 0.5, respectively. Few tumors have average QLOH value
near 1.0 at 3q loci, in contrast to the other regions.
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they showed increased gain toward the more distal markers
(Figure 4 ).
Discussion
AI in TGCTs
AI studies of TGCT are complicated by tumor hetero-
geneity, where both tumor tissues of different histologic types
and also normal cells often are intermingled. Furthermore,
the tumor can be genetically heterogeneous within a
morphologically homogeneous component. Thus, AI can be
the result of LOH masked by both normal cells and by other
subclones of the tumor with retained heterozygosity. Qual-
itative and semiquantitative histological examinations of
tumor cross sections ensure better interpretation of AI
studies. In this study, the percentage of intact tumor tissue
was estimated in all biopsies used for DNA isolation, and this
was taken into account when scoring LOH among the AI
cases. However, detection of AI can also reflect gain of one of
the alleles. For better interpretation of the AIs in our study, we
therefore compared our data with the results of a separate
study [31] , where 33 of the same tumors were analyzed by
CGH. That study showed net loss at chromosome arms 5q
and 18q, in 48% and 52% of the tumors, respectively, and
none of the tumors revealed gain. At distal 12q and 3q, 60%
and 12% of the tumors showed gain, and none showed loss.
When comparing these results with the present study, one
Figure 4. Closing in on TGCT1. This panel shows the pattern of the five
tumors with breakpoints in their X marker peak heights, compared to their
reference peak heights. The filled circles indicate markers with increased gain
compared to their neighboring markers ( open circles ). DXS1193 was the only
marker showing increased gain in all these tumors.
Figure 3. Chromosome 12 alterations in a mixed TGCT. (A ) The electropherograms of three markers amplified in blood (constitutional ) and tumor DNA show the
allele intensities in relative fluorescence units ( y -axis and peak heights in boxes below the alleles ). The tumor showed gradually stronger AI ( decreasing QLOH )
toward the distal 12q loci. A second PCR of the same markers and templates confirmed the results, and showed QLOH values of 0.20, 0.97, and 0.77. The fourth
investigated 12q marker, D12S357 (not shown ), was constitutionally homozygous, and thus not informative. (B ) CGH of the tumor showed gain of the whole
chromosome with additional amplification of two regions. The central curve shows the average fluorescence ratio of 14 chromosomes between tumor and reference
DNA, whereas the two flanking curves represent the 95% confidence interval. The gain of the short arm might reflect the isochromosome 12p, a frequent and
characteristic aberration in germ cell tumors, but interestingly, the distal part of the long arm is also amplified. A QLOH value of 0.19 ( as for D12S367 ) will almost
exclusively, in any AI / LOH study, be interpreted as LOH. However, upon comparison with CGH data, we see that the AI in this tumor is most likely caused by
amplification of genetic material ( complete CGH — copy number karyotypes — for all tumors will be published elsewhere; Ref. [ 31 ] ).
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should bear in mind the different resolutions inherent in the
two methods. Furthermore, skewed intensities between the
homologues, but unchanged overall copy number (as is the
case with uniparental disomy), are only detected by the AI
approach, whereas simultaneous gain of both homologues is
only revealed by CGH.
We reported at the 2000 AACR Annual Meeting [32] the
high frequencies of AI at 3q, 5q, 12q, and 18q. This was
recently confirmed by Faulkner et al. [33] who reported
frequencies of LOH comparable to our frequencies of AI.
However, this study did not take into account that the
imbalances also might reflect gain of genetic material.
Frequent Changes at 3q are Due to Both Loss and Trisomy
The overall frequency of AI was significantly higher for
the 3q loci than for any other investigated loci. However,
only 4 of 33 TGCTs investigated by CGH showed changes
(all gain) at distal 3q. This indicates that AI detected at 3q
usually reflects trisomy, which will be hidden by a CGH
approach by a near triploid background. This is in keeping
with previous cytogenetic findings [5] . Furthermore, studies
have indicated trisomy 3 to be more frequent in non-
seminomas than in seminomas [5,7 ] , which is in agree-
ment with our AI data for the 3q loci. However, the
investigated 3q loci also showed the highest frequencies
of LOH, indicating that a substantial share of the changes at
3q is not caused by trisomy. In addition, the group of tumors
with lowest QLOH values was not correlated with any
aberration seen by CGH, indicating the involvement of a
relatively small region. Because the seminomas and non-
seminomas both show similar and high frequencies of LOH
for the 3q markers, the loss of genetic sequences on
chromosome 3 is most likely an early event in TGCT
development, and the 3q27- ter candidate region may
harbor a TGCT suppressor gene.
AI at 5q and 18q is Due to Loss of Genetic Material
Our AI data, together with the corresponding CGH results,
give evidence that the frequent imbalances at 5q and 18q
result from loss of genetic material. The observed LOH
frequencies at these genomic regions are in keeping with
previous studies [34–36] , and are similar in both semi-
nomas and nonseminomas. Thus, loss of genetic material
from these regions appears to be an early event in the TGCT
development.
AI at 12q Loci is Due to Gain of Genetic Material
Isochromosome 12p, i(12p), is present in more than 80%
of human TGCTs [7] . However, Rodriguez et al. [7 ]
hypothesized that the pathogenetic trigger in TGCT is not
the gain of 12p, but the simultaneous loss of a putative
tumor-suppressor gene at 12q. LOH has previously been
reported in 50%of TGCTs at one ormore loci along 12q [37] .
In the present study, we show a similar frequency of AI (55%)
at 12q loci. However, the frequent gain of 12q sequences
seen by CGH, and not a single event of loss, together with
significantly lower frequencies of LOH than at all the other
investigated regions, suggests that AI scored at 12q loci
reflects gain, rather than loss, of genetic material. The
significantly higher proportion of AI among nonseminomas
than among seminomas indicates that this gain is involved in
the progression of seminomas into nonseminomas.
The results of the ITCLC study showed increasing
linkage evidence for the 12q markers as they approached
the telomere [19] . This correlates with the gain at distal
12q seen by CGH in some of the tumors (Figure 3B ).
Microsatellites are underrepresented in subtelomeric
regions [38] , and analyses of more distal markers could
reveal even stronger evidence of linkage in the ITCLC
study.
AI/LOH at Syntenic Loci
Due to the low number of breakpoints in the AI /LOH
pattern, we have not defined any smallest region of
overlapping imbalances within the autosomal regions. This
might indicate that it is not the loss or gain of one
particular gene, but the unison copy number change of
several genes along a chromosomal region that is
important for TGCT development. The clustering of known
tumor-suppressor genes at 5q21 and 18q21 supports this
theory.
Closing in on TGCT1?
Our results on the X chromosome are in agreement with
molecular cytogenetic studies on TGCT, showing a general
overrepresentation of the X chromosome in the tumor DNA
[39–41] , and thus indicating the existence of one or more
genes on the X chromosome which, upon up-regulation,
contributes to TGCT development. Recently, Rapley et al.
[20] found evidence for a TGCT susceptibility locus,
TGCT1, at Xq27, between the markers DXS8028 and
FMR1Di (2.5 female cM proximal to DXS1215). However,
this region was limited by only one recombination event on
each side of the region. Five of our investigated tumors
showed breakpoints in the amplification level among the
investigated X chromosome markers (Figure 4 ). Although
speculative, one may hypothesize from these somatic
changes that TGCT1 may have a more distal map position,
or a second target gene is present on Xq, distal of DXS1215
and TGCT1.
Similar Frequencies of Genetic Changes between Familial /
Bilateral and Sporadic TGCTs Speak in Disfavor of One
Single Susceptibility Gene
A segregation analysis on TGCT families and an
analysis based on the frequency of bilateral disease gave
evidence for an autosomal recessive inheritance mode
[18,42] . Individuals with familial /bilateral TGCT may thus
have inherited two inactive alleles of a tumor-suppressor
gene with limited penetrance. Those with sporadic TGCT
are then thought to be heterozygous for the gene, and
somatic mutation, imprinting, and loss are possible second
steps in the total inactivation of the tumor-suppressor
gene.
The fact that none of the candidate regions showed
significantly different frequencies of genetic changes
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between the familial /bilateral and the sporadic tumor
groups speaks in disfavor of the existence of one single
TGCT susceptibility gene. However, the high frequencies
of genetic changes within the investigated regions
suggest their importance in the development of primary
TGCTs. One may hypothesize that different genes
located within the different candidate regions are
responsible for the predisposition in different individuals,
or that several genes together give an elevated risk of
TGCT.
Based on the model seminomas arise from carcinomas
in situ, and may develop into nonseminomas [5] , our data
suggest that gain of genetic material at distal Xq, and
losses at 5q and 18q, contribute to establishment of
seminomas, whereas imbalances at 3q and gain at distal
part of 12q are associated with further progression into
nonseminomas.
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